A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for
Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant
Fabrice André, MD, PhD (Medicine Oncology Department, Goustave Roussy, Paris)
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)